Future directions in vasodilator therapy for heart failure

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Vasodilator therapy has become a major pharmacologic approach for improving left ventricular function, and consequently, vasodilator drugs are being used increasingly in the treatment of heart failure. Ideally, vasodilator drugs used in the long-term management of heart failure should show clearly defined pharmacodynamic effects. These include reduced impedance to left ventricular ejection, increased venous capacitance, increased left ventricular ejection fraction and reduced heart size, absence of neurohormonal stimulation, and slowed progression of left ventricular dysfunction. The mechanisms of action and sites of activity of the various vasodilator drugs currently available vary considerably, and none as yet has proved ideal for the treatment of heart failure or hypertension. The complexity surrounding the multiple vasoconstrictor mechanisms involved in heart failure has led to a rationale for combined vasodilator therapy and certain combinations are discussed. From a therapeutic standpoint, the development of drugs with multiple mechanisms of action is particularly attractive. Flosequinan is a new vasodilator agent whose cellular mechanism of action remains uncertain. Flosequinan has the advantage of being able to relax both arterial and venous beds and as such may be particularly beneficial in the treatment of heart failure.

Original languageEnglish (US)
Pages (from-to)969-974
Number of pages6
JournalAmerican Heart Journal
Volume121
Issue number3 PART 1
DOIs
StatePublished - Jan 1 1991

Fingerprint

Vasodilator Agents
flosequinan
Heart Failure
Treatment Failure
Therapeutics
Left Ventricular Dysfunction
Vasoconstrictor Agents
Electric Impedance
Left Ventricular Function
Stroke Volume
Direction compound
Hypertension
Pharmaceutical Preparations

Cite this

Future directions in vasodilator therapy for heart failure. / Cohn, Jay N.

In: American Heart Journal, Vol. 121, No. 3 PART 1, 01.01.1991, p. 969-974.

Research output: Contribution to journalArticle

@article{94f8a00271b4469f98d8eb6f22fb91d4,
title = "Future directions in vasodilator therapy for heart failure",
abstract = "Vasodilator therapy has become a major pharmacologic approach for improving left ventricular function, and consequently, vasodilator drugs are being used increasingly in the treatment of heart failure. Ideally, vasodilator drugs used in the long-term management of heart failure should show clearly defined pharmacodynamic effects. These include reduced impedance to left ventricular ejection, increased venous capacitance, increased left ventricular ejection fraction and reduced heart size, absence of neurohormonal stimulation, and slowed progression of left ventricular dysfunction. The mechanisms of action and sites of activity of the various vasodilator drugs currently available vary considerably, and none as yet has proved ideal for the treatment of heart failure or hypertension. The complexity surrounding the multiple vasoconstrictor mechanisms involved in heart failure has led to a rationale for combined vasodilator therapy and certain combinations are discussed. From a therapeutic standpoint, the development of drugs with multiple mechanisms of action is particularly attractive. Flosequinan is a new vasodilator agent whose cellular mechanism of action remains uncertain. Flosequinan has the advantage of being able to relax both arterial and venous beds and as such may be particularly beneficial in the treatment of heart failure.",
author = "Cohn, {Jay N}",
year = "1991",
month = "1",
day = "1",
doi = "10.1016/0002-8703(91)90228-A",
language = "English (US)",
volume = "121",
pages = "969--974",
journal = "American Heart Journal",
issn = "0002-8703",
publisher = "Mosby Inc.",
number = "3 PART 1",

}

TY - JOUR

T1 - Future directions in vasodilator therapy for heart failure

AU - Cohn, Jay N

PY - 1991/1/1

Y1 - 1991/1/1

N2 - Vasodilator therapy has become a major pharmacologic approach for improving left ventricular function, and consequently, vasodilator drugs are being used increasingly in the treatment of heart failure. Ideally, vasodilator drugs used in the long-term management of heart failure should show clearly defined pharmacodynamic effects. These include reduced impedance to left ventricular ejection, increased venous capacitance, increased left ventricular ejection fraction and reduced heart size, absence of neurohormonal stimulation, and slowed progression of left ventricular dysfunction. The mechanisms of action and sites of activity of the various vasodilator drugs currently available vary considerably, and none as yet has proved ideal for the treatment of heart failure or hypertension. The complexity surrounding the multiple vasoconstrictor mechanisms involved in heart failure has led to a rationale for combined vasodilator therapy and certain combinations are discussed. From a therapeutic standpoint, the development of drugs with multiple mechanisms of action is particularly attractive. Flosequinan is a new vasodilator agent whose cellular mechanism of action remains uncertain. Flosequinan has the advantage of being able to relax both arterial and venous beds and as such may be particularly beneficial in the treatment of heart failure.

AB - Vasodilator therapy has become a major pharmacologic approach for improving left ventricular function, and consequently, vasodilator drugs are being used increasingly in the treatment of heart failure. Ideally, vasodilator drugs used in the long-term management of heart failure should show clearly defined pharmacodynamic effects. These include reduced impedance to left ventricular ejection, increased venous capacitance, increased left ventricular ejection fraction and reduced heart size, absence of neurohormonal stimulation, and slowed progression of left ventricular dysfunction. The mechanisms of action and sites of activity of the various vasodilator drugs currently available vary considerably, and none as yet has proved ideal for the treatment of heart failure or hypertension. The complexity surrounding the multiple vasoconstrictor mechanisms involved in heart failure has led to a rationale for combined vasodilator therapy and certain combinations are discussed. From a therapeutic standpoint, the development of drugs with multiple mechanisms of action is particularly attractive. Flosequinan is a new vasodilator agent whose cellular mechanism of action remains uncertain. Flosequinan has the advantage of being able to relax both arterial and venous beds and as such may be particularly beneficial in the treatment of heart failure.

UR - http://www.scopus.com/inward/record.url?scp=0026061174&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026061174&partnerID=8YFLogxK

U2 - 10.1016/0002-8703(91)90228-A

DO - 10.1016/0002-8703(91)90228-A

M3 - Article

C2 - 2000775

AN - SCOPUS:0026061174

VL - 121

SP - 969

EP - 974

JO - American Heart Journal

JF - American Heart Journal

SN - 0002-8703

IS - 3 PART 1

ER -